-
TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio, BioNTech, BiOneCure Therapeutics
09 Apr 2024 17:00 GMT
… trials, visit @ TROP-2 Inhibitors Treatment Drugs … AstraZeneca, Kelun Biotech, Merck, DualityBio, … Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics … , Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD …
-
PI3K Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain
21 Mar 2024 17:00 GMT
… Inhibitors drugs to improve the treatment landscape. … therapies, Small molecule, Vaccines, Polymers, Peptides, … ImmunityBio, Inc., SQZ Biotechnologies, Teon Therapeutics, Inc … Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, …
-
Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 - ResearchAndMarkets.com
13 Mar 2024 13:11 GMT
… Pan-Provincial Vaccine Enterprise
Parnell Pharmaceuticals
Par Pharmaceutical
PDL BioPharma
PDS Biotechnology
Penwest Pharmaceuticals
Pernix … Heart Institute
TFF Pharmaceuticals
TG Therapeutics
Therakine
TherapeuticsMD
Theravance
Theravance Biopharma
The …
-
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Feb 2024 00:30 GMT
… with Orbicular Pharmaceutical Technologies Private … Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines … FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment … for clinical trials. These …
-
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript
28 Feb 2024 15:40 GMT
… Transcript February 26, 2024
Theravance Biopharma, Inc. beats … anticipated timing of clinical trials, regulatory filings and … convenient and durable effective treatment option. While non-pharmacological … later, the FDA approved a second drug called Droxidopa …
-
Theravance Biopharma to Participate in an Upcoming March 2024 Investor Conference
22 Feb 2024 14:21 GMT
… Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines … FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment … please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the …
-
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
14 Feb 2024 13:15 GMT
… Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines … FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment … please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the …
-
Crohn's Disease Treatment Drug Market is Expected to Showcase a Significant Growth During Study Period (2019–2032) | DelveInsight
06 Feb 2024 18:00 GMT
… clinical trials, visit @ Crohn's Disease Treatment Drugs … Theravance Biopharma, TaiwanJ Pharmaceuticals, Celularity, Cerecor, GlaxoSmithKline, KangStem Biotech, … Trio medicines, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, JHL Biotech, Innovative …
-
Theravance’s Yupelri falls short in Phase IV COPD trial
05 Feb 2024 15:40 GMT
US-based biotech Theravance Biopharma’s chronic obstructive pulmonary disease (COPD) drug Yupelri (revefenacin … the FDA – it was secured in November 2018 following two clinical trials … from the Phase III NOTUS trial (NCT04456673), where Dupixent reduced …
-
Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Post FY2024 Earnings of ($0.80) Per Share
30 Jan 2024 08:18 GMT
… stock.
About Theravance Biopharma
(Get Free Report)
Theravance Biopharma, … commercialization of organ-selective medicines. Its purpose is … generation of small molecule drugs designed to better … pursuit of its purpose, Theravance Biopharma applies insights and …